Literature DB >> 28919578

Selectin-independent adhesion during ovarian cancer metastasis.

Nadezhda A Khaustova1, Diana V Maltseva2, Leticia Oliveira-Ferrer3, Christine Stürken4, Karin Milde-Langosch5, Julia A Makarova6, Sergey Rodin7, Udo Schumacher8, Alexander G Tonevitsky9.   

Abstract

PURPOSE: Ovarian cancer (OvCa) progression mainly takes place by intraperitoneal spread. Adhesion of tumor cells to the mesothelial cells which form the inner surface of the peritoneum is a crucial step in this process. Cancer cells use in principle different molecules of the leukocyte adhesion cascade to facilitate adhesion. This cascade is initiated by selectin-ligand interactions followed by integrin - extracellular matrix protein interactions. Here we address the question whether all tumor cells predominantly employ selectin-dependent leukocyte-like adhesion cascade (SDAC) or whether they use integrin mediated adhesion for OvCa progression as well.
METHODS: A comparative transcriptomic analysis of the human OvCa cell lines OVCAR8 and SKOV3 was performed. Intraperitoneal xenograft model of OVCAR8 cells was used to determine whether there is a correlation between SDAC gene expression and the metastatic potential of the control cells and the cells overexpressing c-Fos. Transcriptomic analysis of OVCAR8 and SKOV3 samples was performed using microarrays.
RESULTS: One-third of the protein-coding genes involved in SDAC exhibited lower expression levels in OVCAR8 than in SKOV3 cells. In contrast to SKOV3 cells, c-Fos overexpression in OVCAR8 cells did not significantly influence the expression of SDAC genes. Intraperitoneal xenograft model of OVCAR8 cells unexpectedly demonstrated that the aggressiveness of OVCAR8 tumors was not depended on the c-Fos expression level and was comparable to that of SKOV3 control tumors. Gene expression analysis of tumors suggests that SKOV3-derived tumor progression was mainly depended on SDAC. Progression of OVCAR8 tumors relied on other cell adhesion molecules that do not interact with selectins.
CONCLUSIONS: High expression of c-Fos in ovarian cancer cells is not always associated with reduced metastatic potential. Low expression level of SDAC genes may not ensure low OvCa metastatic potential hence alternative adhesion mechanisms involving laminin-integrin interactions exist as well.
Copyright © 2017 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved.

Entities:  

Keywords:  Integrin; Laminin; Metastasis; Ovarian cancer; Selectin; Tumor cell adhesion

Mesh:

Substances:

Year:  2017        PMID: 28919578     DOI: 10.1016/j.biochi.2017.09.009

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  4 in total

1.  Differences in Medium-Induced Conformational Plasticity Presumably Underlie Different Cytotoxic Activity of Ricin and Viscumin.

Authors:  Pavel Volynsky; Diana Maltseva; Valentin Tabakmakher; Eduard V Bocharov; Maria Raygorodskaya; Galina Zakharova; Elena Britikova; Alexander Tonevitsky; Roman Efremov
Journal:  Biomolecules       Date:  2022-02-11

Review 2.  The functional role of integrins during intra- and extravasation within the metastatic cascade.

Authors:  Greta Sökeland; Udo Schumacher
Journal:  Mol Cancer       Date:  2019-01-18       Impact factor: 27.401

3.  Fra-2 overexpression upregulates pro-metastatic cell-adhesion molecules, promotes pulmonary metastasis, and reduces survival in a spontaneous xenograft model of human breast cancer.

Authors:  Sabrina Arnold; Jan Kortland; Diana V Maltseva; Stepan A Nersisyan; Timur R Samatov; Susanne Lezius; Alexander G Tonevitsky; Karin Milde-Langosch; Daniel Wicklein; Udo Schumacher; Christine Stürken
Journal:  J Cancer Res Clin Oncol       Date:  2021-10-24       Impact factor: 4.553

4.  LAMA4-Regulating miR-4274 and Its Host Gene SORCS2 Play a Role in IGFBP6-Dependent Effects on Phenotype of Basal-Like Breast Cancer.

Authors:  Maxim Shkurnikov; Sergey Nikulin; Stepan Nersisyan; Andrey Poloznikov; Shan Zaidi; Ancha Baranova; Udo Schumacher; Daniel Wicklein; Alexander Tonevitsky
Journal:  Front Mol Biosci       Date:  2019-11-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.